Avanza Fonder AB Takes $752,000 Position in Corteva, Inc. $CTVA

Avanza Fonder AB acquired a new stake in Corteva, Inc. (NYSE:CTVA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,223 shares of the company’s stock, valued at approximately $752,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of Corteva by 307.2% during the 4th quarter. Brighton Jones LLC now owns 15,588 shares of the company’s stock worth $888,000 after purchasing an additional 11,760 shares during the last quarter. Woodline Partners LP lifted its position in Corteva by 40.3% during the first quarter. Woodline Partners LP now owns 57,919 shares of the company’s stock worth $3,645,000 after buying an additional 16,644 shares during the period. American Century Companies Inc. boosted its stake in Corteva by 9.8% in the 2nd quarter. American Century Companies Inc. now owns 147,267 shares of the company’s stock worth $10,976,000 after buying an additional 13,102 shares during the last quarter. Coldstream Capital Management Inc. boosted its stake in Corteva by 11.4% in the 2nd quarter. Coldstream Capital Management Inc. now owns 14,075 shares of the company’s stock worth $1,049,000 after buying an additional 1,441 shares during the last quarter. Finally, Waterloo Capital L.P. acquired a new position in shares of Corteva during the 2nd quarter valued at about $272,000. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva Stock Up 1.8%

Shares of NYSE CTVA opened at $82.00 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.96 and a current ratio of 1.43. Corteva, Inc. has a 1 year low of $53.40 and a 1 year high of $82.26. The stock’s 50-day simple moving average is $75.76 and its 200-day simple moving average is $69.53. The firm has a market cap of $55.05 billion, a price-to-earnings ratio of 51.90, a PEG ratio of 2.75 and a beta of 0.72.

Corteva (NYSE:CTVA) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.Corteva’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, equities analysts anticipate that Corteva, Inc. will post 2.96 earnings per share for the current fiscal year.

Corteva Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 16th. Investors of record on Monday, March 2nd were paid a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Monday, March 2nd. Corteva’s dividend payout ratio (DPR) is 45.57%.

Insiders Place Their Bets

In related news, insider Brian Titus sold 8,311 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares of the company’s stock, valued at $619,289.50. The trade was a 50.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.14% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on CTVA. The Goldman Sachs Group reiterated a “buy” rating and issued a $88.00 target price on shares of Corteva in a report on Thursday, February 5th. Zacks Research downgraded shares of Corteva from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 20th. Mizuho lifted their price target on shares of Corteva from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday, February 17th. JPMorgan Chase & Co. lowered shares of Corteva from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $75.00 to $77.00 in a research report on Thursday, February 5th. Finally, CICC Research lifted their target price on shares of Corteva from $70.00 to $80.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Corteva has a consensus rating of “Moderate Buy” and a consensus target price of $82.90.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.